Optical Coherence Tomography Angiography in Type 1 Diabetes Mellitus. Report 1: Diabetic Retinopathy

Marina Barraso¹, Aníbal Alé-Chilet¹, Teresa Hernández¹, Cristian Oliva¹, Irene Vinagre²,⁵, Emilio Ortega²,⁴,⁵, Marc Figueras-Roca¹,⁵, Anna Sala-Puigdollers¹,⁵, Cristina Esquinas³, Enric Esmatjes²,⁵, Alfredo Adán¹,⁵, and Javier Zarranz-Ventura¹,⁵

¹ Institut Clínic d’Oftalmologia (ICOF), Hospital Clinic, Barcelona, Spain
² Diabetes Unit, Institut Clínic de Malalties Digestives i Metabòliques (ICMDM), Hospital Clinic, Barcelona, Spain
³ Respiratory Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
⁴ Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Spain
⁵ August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

Correspondence: Javier Zarranz-Ventura, Institut Clínic d’Oftalmologia (ICOF), Hospital Clinic, Carrer de Sabino Arana, 1, 08028 Barcelona, Spain. e-mail: jzarranz@hotmail.com

Received: May 8, 2020
Accepted: August 31, 2020
Published: September 30, 2020

Keywords: diabetic retinopathy; optical coherence tomography angiography; retinal blood flow; type 1 diabetes mellitus; retinal imaging

Citation: Barraso M, Alé-Chilet A, Hernández T, Oliva C, Vinagre I, Ortega E, Figueras-Roca M, Sala-Puigdollers A, Esquinas C, Esmatjes E, Adán A, Zarranz-Ventura J. Optical coherence tomography angiography in type 1 diabetes mellitus. report 1: diabetic retinopathy. Trans Vis Sci Tech. 2020;9(10):34, https://doi.org/10.1167/tvst.9.10.34

Purpose: The purpose of this study was to evaluate specifically in type 1 diabetes mellitus (DM) individuals the relationship between perifoveal superficial capillary plexus (SCP) parameters assessed by optical coherence tomography angiography (OCTA) and diabetic retinopathy (DR) grade.

Methods: Cross-sectional analysis of a large scale prospective OCTA trial cohort (ClinicalTrials.gov NCT03422965). A total of 1186 eyes (593 individuals), 956 type 1 DM eyes (478 patients), and 230 control eyes (115 healthy volunteers) were included in this study. DR stage was graded according to the International Classification. OCTA imaging was performed with a commercially available device (Cirrus HD-OCT). Vessel density (VD), perfusion density (PD), and foveal avascular zone (FAZ) area, perimeter and circularity measurements were quantified in the SCP and receiver operating characteristic (ROC) curves were constructed for each OCTA parameter.

Results: VD and PD (in both 3 × 3 and 6 × 6 mm captures) were inversely associated with DR stage (P < 0.001 in all cases) in a multiple regression analysis after controlling by age, gender, signal strength index, axial length, and DM duration. Greater FAZ area and perimeter and conversely lower circularity measurements were observed as DR severity increased in both scanning protocols (P < 0.05 in all cases).

Conclusions: In type 1 DM individuals, OCTA provides an objective, continuous, and reliable method for accurate quantification of VD, PD, and FAZ parameters in the SCP, which ultimately correlate with DR stages.

Translational Relevance: Objective OCTA measurements of the retinal microvasculature could substitute the clinical DR classification in patients with type 1 DM, identify patients at risk of DR progression, and inform treatment decisions to modify the evolution of the disease.

Introduction and Purpose

Diabetic retinopathy (DR) is a clinically diverse entity originating from the alteration of small retinal vessels. A selective loss of pericytes and endothelial cells, as well as the thickening of the basal membrane in retinal capillaries, occurs as a result of a long period of exposure to elevated glucose levels in blood, damaging the retinal vessels and affecting the retinal flow in a time dependent manner.¹ Until recently, the only technique that permitted the evaluation of vascular flow in the retina of patients with diabetes mellitus (DM) was fluorescein angiography (FA), a test that requires an intravenous injection of dye.² Because this technique cannot visualize or quantify separately the main two major networks of capillaries, the superficial capillary plexus (SCP) and deep capillary plexus (DCP), its role...
in the understanding of selective vessel plexus implication in DR appears limited. For these two reasons, in the research setting, FA has been relegated by optical coherence tomography angiography (OCTA), a novel noninvasive retinal imaging procedure.

OCTA represents an interesting opportunity to evaluate the perifoveal vascular network at different moments of the disease, with the potential of being an excellent tool to identify early changes (capillary dilatation, foveal avascular zone [FAZ] enlargement, impaired capillary perfusion in paramacular areas, or presence of microaneurysms) in a noninvasive way.

Many studies have been carried out in the last years to evaluate the perifoveal vascular flow and FAZ features in patients with diabetes using OCTA. However, the vast majority represent a relatively short series of patients, they rarely have a control group, and, more importantly, almost all of them have been performed in patients with type 2 DM. Type 2 DM has a completely different pathophysiology than type 1 DM, and it commonly affects older patients with other comorbidities, such as hypertension or dyslipidemia, that may affect the quantification of OCTA images.

With this aim, we designed a prospective research project directed to study the retinal vascular network through OCTA in a large cohort of patients with type 1 DM (registered in ClinicalTrials.gov, NCT03422965). In agreement with the Diabetes Unit of the Endocrinology Department, the routine yearly fundus retinography of patients with type 1 DM was replaced by a comprehensive ocular examination, which included an extensive battery of OCT and OCTA image collection. Associations between ocular data derived from this examination and demographic and systemic data from current and last 5 years blood test data were evaluated, with the objective to identify possible biomarkers of the disease.

The purpose of this specific report is to determine objectively in a cross-sectional analysis the characteristics of the perifoveal capillary network in patients with type 1 DM and to study their relationship with the DR grade compared to those observed in a control group of healthy volunteers. We aim to evaluate the potential of OCTA as a new tool to detect objective parameters of DM status in the perifoveal vascular network in a large series of patients with type 1 DM, which may have direct implications in the systemic management of these patients.

**Methods**

**Study Design and Study Protocol**

A cross sectional, exploratory study was conducted in a large cohort of patients with type 1 DM recruited from the Diabetes Unit of Hospital Clinic in a 24-month period (May 2017–May 2019), with prospective collection of OCTA images and relevant ocular and systemic clinical data. The study protocol has been described elsewhere. This project was approved by the Institutional Review Board of Hospital Clinic of Barcelona (study protocol version 0.2, 23/11/2016) and it is registered in the Clinical Trials website (ClinicalTrials.gov NCT03422965). Written informed consent was obtained for all participants.

**Inclusion and Exclusion Criteria**

Patients with type 1 DM undergoing yearly follow-up visits, as per routine clinical care at the Diabetes Unit of our center, were invited to participate in the study. Those willing to participate were referred for a comprehensive ocular examination. Controls were collected from healthy volunteers recruited in the general population after social media campaigns supported by the Communications department of the hospital. Exclusion criteria include concomitant ocular pathologies, macular edema, presence of macular cysts, previous ocular surgery, previous macular laser, previous ocular treatment, including intravitreal therapies, media opacities, and inability to perform complete ocular examinations, including retinal imaging (OCT, OCTA, fundus retinographies, biometry, etc.), as well as inability to give written informed consent to participate in the study. A consolidated standard of reporting trials (CONSORT)-style flow chart describing included and excluded eyes in the study and each individual OCTA analysis is presented in Figure 1.

**Interventions: Ocular and Systemic Data**

All participants underwent a complete ocular examination. Clinical data collected included: best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, intraocular pressure measurement, retinal fundus examination, and biometry (IOL Master; Carl Zeiss Meditec, Dublin, CA). Diabetic retinopathy stage was graded in all study eyes using the International Clinical Diabetic Retinopathy Disease Severity Scale. A comprehensive battery of OCT and OCTA images was performed as described below.

Systemic status of the diabetic disease was evaluated in routine clinical care examinations in the Diabetes Unit of the Endocrinology service, and clinical data collected included: age, gender, smoking habit, duration of the disease, type of treatment (insulin doses, lipid-lowering, antihypertensive, and antiplatelet drugs), concomitant pathology (hypertension, dyslipidemia, and macrovascular complications), body mass index (BMI), hemogram, HbA1c, lipid
Statistical Analysis

In order to describe the qualitative variables, absolute frequencies and percentages were used. The description of quantitative variables was performed using the mean, standard deviation (SD), median, and quartiles. The Kolmogorov-Smirnov test was used to assess the normality of distributions. Clinical variables, OCTA, and structural parameters according to the DR grade were compared using a Generalized Estimating Equation (GEE) in order to control the potential bias of bilaterality and adjusted by age, gender, SSI, axial length, and DM disease duration from diagnosis. ANOVA or Kruskal-Wallis test (if normality was not assumed) with Bonferroni correction was used in multiple comparisons between groups in the case of quantitative variables. The analysis at the patient level was analyzed using linear regression for continuous variables or Mantel-Hansel test for categorical variables. Receiver operating curves (ROC) were constructed to evaluate the area under the curve (AUC) of each OCTA parameter by subgroups (controls, no diabetic retinopathy, diabetic retinopathy). For all the tests, $P$ values $< 0.05$ were considered statistically significant. The statistical package R Studio (version 2.5) was used for the statistical analyses.

Results

A total number of 1186 of eyes of 593 individuals were originally included in the study. Four hundred seventy-eight patients with type 1 DM (956 eyes) and 115 healthy controls (230 eyes) underwent a
complete ocular examination during the predetermined timeframe. Exclusion criteria were applied and 181 eyes were excluded due to previous ocular surgery (93 eyes), previous ocular treatment (24 eyes), previous macular laser (21 eyes), macular edema (9 eyes), or concomitant ocular pathology (71 eyes), such as glaucoma (19 eyes), amblyopia (16 eyes), myopia magna, or axial length > 27 mm (8 eyes), and other causes (28 eyes), such as retinal vein occlusions or uveitis. OCTA images from 1009 eyes were analyzed. A detailed description of OCTA images excluded due to artifacts, poor OCTA image quality (defined as SSI < 7), or incorrect FAZ delineation by the built-in software for each OCTA parameter analysis is presented in Figure 1.

Mean age for patients with diabetes was 40 ± 12.4 (standard deviation [SD]) years and the mean disease duration was 20 ± 10.8 years. Mean age for healthy controls was 43 ± 14.1 years. All demographic characteristics are shown in Supplementary Table S1. The distribution of DR grades was no DR in 53.4% (n = 539) of the examined eyes, mild non-proliferative diabetic retinopathy (NPDR) in 21.2% (n = 214), moderate NPDR in 3.3% (n = 34), severe NPDR in 0.4% (n = 5), and finally proliferative DR (previously treated with panretinal photocoagulation in all cases) in 1.3% (n = 14) of the study eyes. All baseline characteristics of study eyes according to DR stage distribution are summarized in Supplementary Table S2. All OCTA measurements were controlled and adjusted by diabetic retinopathy grade baseline characteristics in a multivariate analysis.

Vessel Density, Perfusion Density, and Diabetic Retinopathy Grade

Figure 2 depicts examples of 3 × 3 mm and 6 × 6 mm OCTA images of control eyes and different DR stages. The mean values of VD, perfusion density (PD), FAZ area, perimeter, and circularity in 3 × 3 and 6 × 6 mm captures in both diabetic and control patients are shown in Figure 3 and Figure 4 and in Table 1.

In 3 × 3 mm captures, a significant association was observed between VD and DR stage, showing lower VD with greater levels of DR stage and statistically significant differences between the different disease severity groups and controls (P < 0.001), after adjusting data by age, gender, SSI, axial length, and duration of DM disease. Differences between each different DR groups are detailed in Figure 3. PD also showed significant differences (P < 0.001 in all cases) between the DR stage groups with lower PD in greater levels of DR severity. Similar findings were observed with the 6 × 6 mm captures, as shown in Figure 3 and Table 1.

Foveal Avascular Zone Measurements and Diabetic Retinopathy Grade

FAZ parameters showed different results in 3 × 3 and 6 × 6 mm scans, as shown in Figure 4. In 3 × 3 mm scans, significant differences were observed in the FAZ area (P = 0.029), FAZ perimeter (P < 0.001), and FAZ circularity (P < 0.001) between controls and the different DR severity groups. Statistically
Figure 3. Vessel density (VD) and perfusion density (PD) measurements and diabetic retinopathy (DR) grade, after adjusting for age, gender, signal strength index (SSI), axial length, and duration of diabetes mellitus disease. Top: VD (left) and PD (right) measurements in the complete scanned area using the 3 × 3 mm scanning protocol. Bottom: VD (left) and PD (right) measurements in the complete scanned area using the 6 × 6 mm scanning protocol. Generalized Estimating Equation (GEE) adjusted for age, gender, signal strength index (SSI), axial length, and duration of diabetes mellitus disease for global $P$ value; pairwise comparisons by Kruskal-Wallis test with Bonferroni correction. $P < 0.05$: (a) vs. Control; (b) vs. No DR; (c) vs. Mild DR; (d) vs. Moderate DR; (e) vs. Severe DR; (f) vs Proliferative DR. (Total number of eyes [3 × 3/6 × 6]: control 189/183, no DR 504/503, mild NPDR 202/198, moderate NPDR 29/30, severe NPDR 4/3, PDR 10/10).

Figure 4. Foveal Avascular Zone (FAZ) measurements and diabetic retinopathy (DR) grade after adjusting for gender, age, SSI, axial length, and duration of diabetes mellitus disease. Top: FAZ area (left), perimeter (middle), and circularity (right) measurements in the complete scanned area using the 3 × 3 mm scanning protocol. Bottom: FAZ area (left), perimeter (middle), and circularity (right) measurements in the complete scanned area using the 6 × 6 mm scanning protocol. Generalized Estimating Equation (GEE) adjusted for age, gender, signal strength index (SSI), axial length, and duration of diabetes mellitus disease for global $P$ value; pairwise comparisons by Kruskal-Wallis test with Bonferroni correction. $P < 0.05$: (a) vs. Control; (b) vs. No DR; (c) vs Mild DR; (d) vs Moderate DR; (e) vs Severe DR; (f) vs Proliferative DR. (Total number of eyes [3 × 3/6 × 6]: control 174/169, no DR 470/461, mild NPDR 180/178, moderate NPDR 26/26, severe NPDR 3/2, PDR 8/8).
significant differences ($P < 0.05$) were found in $2 \times 2$ comparisons between controls and some of the DR groups, as well as between some of the DR groups, as detailed in Figure 4. Similarly, in $6 \times 6$ mm scans significant differences between controls and the DR groups were observed for FAZ area ($P = 0.005$), FAZ perimeter ($P = 0.002$), and FAZ circularity ($P < 0.001$). Statistically significant differences were found in $2 \times 2$ comparisons between controls and some of the DR groups ($P < 0.05$), as well as between some of the different DR groups. All these results are summarized in Figure 4 and Table 1.

Influence of Diabetes Mellitus Duration on OCTA Metrics

Subgroup analysis was performed by duration of DM and groups were defined as A ($< 5$ years), B (5–15 years), and C (> 15 years). Significant differences were observed in the $3 \times 3$ mm scans for VD ($20.8 \pm 1.5$ vs. $20.7 \pm 1.5$ vs. $19.3 \pm 1.9$, $P < 0.001$) and PD ($0.37 \pm 0.02$ vs. $0.37 \pm 0.03$ vs. $0.36 \pm 0.03$, $P < 0.001$) for these 3 subgroups in a linear regression model adjusted for age, gender, SSI, axial length, and DR grade. With regard to the FAZ parameters, no differences were observed for FAZ area ($0.24 \pm 0.08$ vs. $0.23 \pm 0.1$ vs. $0.23 \pm 0.1$, $P = 0.52$) or FAZ perimeter ($2.1 \pm 0.38$ vs. $2.01 \pm 0.47$ vs. $2.11 \pm 0.53$, $P = 0.146$), but significant differences were observed in FAZ circularity ($0.67 \pm 0.08$ vs. $0.67 \pm 0.07$ vs. $0.64 \pm 0.09$, $P = 0.01$). Similar results were observed in the $6 \times 6$ mm scans, and differences were observed for VD ($18.1 \pm 1.2$ vs. $18.0 \pm 1.2$ vs. $17.3 \pm 1.4$, $P < 0.001$), PD ($0.44 \pm 0.03$ vs. $0.44 \pm 0.03$ vs. $0.43 \pm 0.04$, $P < 0.001$) for these 3 subgroups, in a linear regression model adjusted for age, gender, SSI, axial length, and DR grade. No differences were observed for FAZ area ($0.24 \pm 0.09$ vs. $0.23 \pm 0.09$ vs. $0.24 \pm 0.11$, $P = 0.541$) and FAZ perimeter ($1.96 \pm 0.4$ vs. $1.94 \pm 0.43$ vs. $1.97 \pm 0.51$, $P = 0.537$) but FAZ circularity showed significant differences between groups ($0.76 \pm 0.07$ vs. $0.74 \pm 0.08$ vs. $0.73 \pm 0.08$, $P = 0.016$). All these results are presented in Table 2.

Receiver Operating Curve Analysis of OCTA Parameters

ROC were constructed to calculate the AUC for each one of the OCTA parameters in controls, patients with DM with no diabetic retinopathy, and patients with DM with diabetic retinopathy (non-proliferative and proliferative). The ROC curves for OCTA parameters in the $3 \times 3$ mm scans are presented in Figure 5. For VD, the AUC was 0.65, 0.61, and 0.75 in controls, no DR and DR. Proposed cut off points for VD in these subgroups are 19.85, 19.15, and 20.35, respectively. For PD, the AUC was 0.59, 0.58, and 0.67 in controls, no DR and DR. Proposed cut off points for PD in these subgroups are 0.37, 0.37, and 0.37, respectively. FAZ area parameters were also evaluated with ROC curves. For FAZ area, the AUC was 0.52, 0.47, and 0.48 in controls, no DR and DR. Proposed cut off points for FAZ area in these subgroups are 0.36, 0.41, and 0.11, respectively. For FAZ perimeter, the AUC was 0.51, 0.55, and 0.57 in controls, no DR and DR. Proposed cut off points for FAZ perimeter in these subgroups are 2.59, 2.14, and 2.44, respectively. For FAZ circularity, the AUC was 0.57, 0.56, and 0.63 in controls, no DR and DR. Proposed cut off points for FAZ circularity in these subgroups are 0.70, 0.63, and 0.63, respectively.

Discussion

This study highlights the role of OCTA as an objective tool to obtain reliable measurements of the foveal vessel status specifically in patients with type 1 DM, the rarest type of disease. These objective, quantitative, and continuous OCTA-derived measurements ultimately correlate with DR severity, showing gradually lower VD and PD, and greater FAZ changes in the SCP as DR progresses to greater levels of disease.

In the last few years, many OCTA studies have been directed to assess the status of the perifoveal capillary network in DM. However, the vast majority of studies have been performed in patients with type 2 DM, and many of them do not distinguish between patients with type 1 DM and patients with type 2 DM. The pathophysiology of both DM types is considerably different, and patients present well-differentiated clinical characteristics. Whereas type 1 DM is less frequent, commonly affects younger patients, and it is a lifelong standing disease, patients with type 2 DM are more prevalent, they tend to be older, and frequently present concomitant cardiovascular pathologies, such as blood hypertension, metabolic syndrome, or dyslipidemia. Given that age, duration of disease, and some of these other comorbidities have been associated to changes in OCTA metrics, these differences may affect either way the VD or PD measurements in patients with type 1 and type 2 diabetes. For these reasons, there is a paucity of data in the literature about OCTA measurements in type 1 DM eyes.

Very few papers have studied this topic specifically in patients with type 1 DM, and all of them included only a limited number of patients, as shown in Table 3. Carnevali et al. showed in a small series of
| Variable                        | Statistic          | Total (n = 938) | Control (n = 189) | No DR (n = 504) | Mild NPDR (n = 202) | Moderate NPDR (n = 29) | Severe NPDR (n = 4) | Proliferative DR (n = 10) |
|--------------------------------|--------------------|----------------|------------------|----------------|---------------------|------------------------|-------------------|------------------------|
| Vessel density 3 × 3 (mm⁻¹)    | Mean (SD)          | 20.3 (21.9)    | 20.2 (21.7)      | 19.1 (1.9)     | 18.1 (1.6)          | 17.8 (16.2; 18.4)     | 16.5 (16.1; 18.5)   | <0.001                 |
|                               | Median (IQR)       | 21 (20.1; 22)  | 20.5 (19.3; 21.5)| 19.4 (18.2; 20.3)| 18.3 (17.5; 19.2)  | 17.3 (16.2; 18.4)     | 16.5 (16.1; 18.5)   | <0.001                 |
| Perfusion density 3 × 3 (0-1)   | Mean (SD)          | 0.36 (0.03)    | 0.37 (0.03)      | 0.36 (0.03)    | 0.34 (0.03)         | 0.34 (0.01)           | 0.34 (0.03)        | <0.001                 |
|                               | Median (IQR)       | 0.37 (0.35; 0.39)| 0.38 (0.36; 0.39)| 0.36 (0.34; 0.38)| 0.35 (0.34; 0.36)  | 0.34 (0.33; 0.35)     | 0.33 (0.32; 0.37)   | <0.001                 |
| FAZ area 3 × 3 (mm²)           | Mean (SD)          | 0.24 (0.1)     | 0.23 (0.1)       | 0.23 (0.1)     | 0.24 (0.1)          | 0.3 (0.11)             | 0.27 (0.01)        | 0.27 (0.15)            |
|                               | Median (IQR)       | 0.23 (0.17; 0.3)| 0.24 (0.17; 0.29)| 0.22 (0.17; 0.29)| 0.23 (0.17; 0.31)  | 0.32 (0.25; 0.39)     | 0.26 (0.26; 0.28)   | 0.29 (0.14; 0.4)       |
| FAZ perimeter 3 × 3 (mm)        | Mean (SD)          | 2.07 (0.49)    | 2.03 (0.45)      | 2.04 (0.48)    | 2.12 (0.52)         | 2.49 (0.54)            | 2.51 (0.12)        | 2.43 (0.62)            |
|                               | Median (IQR)       | 2.09 (1.78; 2.4)| 2.09 (1.78; 2.4)| 2.05 (1.77; 2.4)| 2.14 (1.77; 2.5)   | 2.59 (2.2; 2.8)       | 2.64 (2.4; 2.6)     | 2.69 (2.23; 2.8)       |
| FAZ circularity 3 × 3 (0-1)     | Mean (SD)          | 0.65 (0.09)    | 0.67 (0.08)      | 0.66 (0.08)    | 0.63 (0.09)         | 0.6 (0.09)             | 0.54 (0.06)        | 0.6 (0.09)             |
|                               | Median (IQR)       | 0.66 (0.66; 0.71)| 0.66 (0.61; 0.72)| 0.65 (0.58; 0.7)| 0.58 (0.54; 0.67)  | 0.55 (0.48; 0.6)      | 0.61 (0.53; 0.69)   | <0.001                 |
| Vessel density 6 × 6 (mm⁻¹)     | Mean (SD)          | 17.7 (1.3)     | 18.1 (1.1)       | 17.2 (1.3)     | 16.9 (1.4)          | 15.9 (1.3)             | 16.7 (16.7; 17.1)   | 16.8 (16.3; 17.1)     |
|                               | Median (IQR)       | 18 (17; 18.6)  | 18.3 (17.6; 18.7)| 18.2 (17.3; 18.7)| 17.5 (16.6; 18.2)  | 17.3 (16.5; 17.9)     | 16 (14.5; 17.5)     | <0.001                 |
| Perfusion density 6 × 6 (0-1)   | Mean (SD)          | 0.44 (0.03)    | 0.44 (0.03)      | 0.43 (0.04)    | 0.42 (0.04)         | 0.39 (0.04)            | 0.43 (0.02)        | <0.001                 |
|                               | Median (IQR)       | 0.45 (0.42; 0.46)| 0.45 (0.43; 0.46)| 0.44 (0.41; 0.45)| 0.44 (0.41; 0.45)  | 0.4 (0.36; 0.43)      | 0.43 (0.42; 0.44)   | <0.001                 |
| FAZ area 6 × 6                 | Mean (SD)          | 840            | 169              | 461            | 178                 | 26                       | 2                       | 8                       | 0.005
Table 1. Continued

| Variable                      | Statistic | Total $(n = 938)$ | Control $(n = 189)$ | No DR $(n = 504)$ | Mild NPDR $(n = 202)$ | Moderate NPDR $(n = 29)$ | Severe NPDR $(n = 4)$ | Proliferative DR $(n = 10)$ | P Value for trend $^a$ |
|-------------------------------|-----------|------------------|---------------------|------------------|----------------------|-----------------------|---------------------|--------------------------|---------------------|
| (mm²)                         | Mean (SD) | 0.24 (0.1)       | 0.23 (0.08)         | 0.23 (0.1)       | 0.24 (0.11)          | 0.31 (0.12)           | 0.29 (0.04)         | 0.27 (0.13)               |                     |
|                              | Median (IQR) | 0.23 (0.17; 0.3) | 0.24 (0.19; 0.29)  | 0.22 (0.16; 0.29) | 0.21 (0.16; 0.3)    | 0.33 (0.24; 0.39)    | 0.29 (0.26; 0.32)    | 0.31 (0.15; 0.39)       |                     |
| FAZ perimeter $6 \times 6$    | n         | 840              | 169                 | 461              | 178                  | 26                    | 8                   | 2                         | 8                   |
| (mm)                         | Mean (SD) | 1.96 (0.46)      | 1.94 (0.4)          | 1.93 (0.44)      | 1.95 (0.51)          | 2.35 (0.57)           | 2.44 (0.37)         | 2.16 (0.61)               |                      |
|                              | Median (IQR) | 1.97 (1.67; 2.3) | 2 (1.76; 2.2)      | 1.93 (1.66; 2.2) | 1.95 (1.64; 2.3)    | 2.4 (2.04; 2.8)      | 2.44 (2.17; 2.7)    | 2.34 (1.72; 2.5)         |                      |
| FAZ circularity $6 \times 6$ | n         | 840              | 169                 | 461              | 178                  | 26                    | 8                   | 2                         | <0.001              |
| (0-1)                         | Mean (SD) | 0.74 (0.08)      | 0.75 (0.06)         | 0.74 (0.07)      | 0.73 (0.08)          | 0.69 (0.09)           | 0.62 (0.09)         | 0.71 (0.11)               |                     |
|                              | Median (IQR) | 0.75 (0.69; 0.79)| 0.76 (0.72; 0.8)   | 0.76 (0.7; 0.79) | 0.75 (0.69; 0.8)    | 0.72 (0.63; 0.76)    | 0.62 (0.55; 0.68)   | 0.7 (0.66; 0.8)           |                     |
| Mean RNFL (microns)          | n         | 943              | 188                 | 511              | 200                  | 30                    | 4                   | 10                        | 0.180                |
|                              | Mean (SD) | 96.3 (10.2)      | 96.5 (9.2)          | 96.7 (9.9)       | 95.4 (11.3)          | 99.3 (10.9)           | 84.8 (13.1)        | 89.5 (13.3)               |                     |
|                              | Median (IQR) | 96 (90; 103)    | 95 (90; 104)       | 97 (91; 103)     | 96 (89; 104)         | 100 (93; 105)        | 84 (73.5; 96)      | 86 (81; 87)               |                     |
| Central macular thickness (microns) | n         | 959              | 188                 | 516              | 207                  | 34                    | 4                   | 10                        | 0.339                |
|                              | Mean (SD) | 262.6 (21.5)     | 262.8 (22.2)        | 261.5 (19.9)     | 264.2 (21.8)         | 269.5 (30.5)          | 281 (21.5)         | 244.8 (39.4)              |                     |
|                              | Median (IQR) | 262 (248; 277)  | 261 (247; 280)     | 262 (249; 275)   | 265 (250; 278)       | 268 (246; 286)       | 280.5 (262.5; 299)  | 230 (228; 266)            |                     |
| Central macular volume (microns³) | n         | 959              | 188                 | 516              | 207                  | 34                    | 4                   | 10                        | 0.716                |
|                              | Mean (SD) | 10.3 (0.6)       | 10.3 (0.5)          | 10.3 (0.4)       | 10.3 (0.9)           | 10.4 (0.6)           | 10.1 (0.9)         | 9.8 (0.8)                 |                     |
|                              | Median (IQR) | 10.3 (10; 10.6) | 10.3 (9.9; 10.6)   | 10.3 (10.6)      | 10.2 (9.9; 10.5)     | 10.3 (10.10.8)       | 10.3 (9.4; 10.8)   | 9.9 (9.7; 10.1)           |                     |
| Mean central macular thickness (microns) | n         | 959              | 188                 | 516              | 207                  | 34                    | 4                   | 10                        | 0.387                |
|                              | Mean (SD) | 284.6 (17.6)     | 285.3 (14.9)        | 284.6 (20.2)     | 283.9 (12.9)         | 286 (17.3)           | 278.8 (25.2)       | 272.6 (22.5)              |                     |
|                              | Median (IQR) | 285 (277; 294) | 285 (274; 295)     | 286 (279; 293)   | 283 (275; 292)       | 285.5 (276; 298)     | 285 (259; 289.5)    | 276 (269; 280)            |                     |

OCTA, optical coherence tomography angiography; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; FAZ, foveal avascular zone; SD, standard deviation; IQR, interquartile range.

$^a$Generalized Estimating Equation (GEE) adjusted for age, gender, signal strength index (SSI), axial length, and duration of diabetes mellitus disease.
Table 2. Influence of Diabetes Mellitus Duration on Optical Coherence Tomography Angiography (OCTA) Metrics

|                      | Statistic | Total (N = 605) | < 5 y (N = 49) | 5-15 y (N = 165) | ≥ 15 y (N = 391) | P Value<sup>a</sup> |
|----------------------|-----------|-----------------|----------------|------------------|------------------|---------------------|
| **3 × 3mm OCTA**     |           |                 |                |                  |                  |                     |
| Vessel density (mm-1)| Mean (SD) | 19.8 (1.9)      | 20.8 (1.5)     | 20.7 (1.5)       | 19.3 (1.9)       | < 0.001<sup>b</sup> |
|                      | Median (IQR) | 20 (18.7; 21.2) | 20.8 (19.9; 22) | 21 (20; 21.8)    | 19.5 (18.2; 20.6) |                     |
| Perfusion density    | Mean (SD) | 0.36 (0.03)     | 0.37 (0.02)    | 0.37 (0.03)      | 0.36 (0.03)      | < 0.001<sup>b</sup> |
|                      | Median (IQR) | 0.37 (0.35; 0.38) | 0.38 (0.36; 0.39) | 0.38 (0.36; 0.39) | 0.36 (0.34; 0.38) |                     |
| Area (mm2)           | Mean (SD) | 0.24 (0.1)      | 0.24 (0.08)    | 0.23 (0.1)       | 0.24 (0.1)       | 0.523               |
|                      | Median (IQR) | 0.23 (0.17; 0.3) | 0.24 (0.17; 0.29) | 0.22 (0.17; 0.28) | 0.23 (0.17; 0.31) |                     |
| Perimeter (mm)       | Mean (SD) | 2.08 (0.5)      | 2.1 (0.38)     | 2.01 (0.47)      | 2.11 (0.53)      | 0.146               |
|                      | Median (IQR) | 2.09 (1.79; 2.4) | 2.07 (1.86; 2.4) | 2.01 (1.77; 2.4) | 2.16 (1.79; 2.5) |                     |
| Circularity          | Mean (SD) | 0.65 (0.09)     | 0.67 (0.08)    | 0.67 (0.07)      | 0.64 (0.09)      | 0.001<sup>b</sup>   |
|                      | Median (IQR) | 0.66 (0.6; 0.71) | 0.68 (0.62; 0.74) | 0.67 (0.62; 0.72) | 0.65 (0.58; 0.7) |                     |
| **6 × 6mm OCTA**     |           |                 |                |                  |                  |                     |
| Vessel density (mm-1)| Mean (SD) | 17.6 (1.3)      | 18.1 (1.2)     | 18 (1.2)         | 17.3 (1.4)       | < 0.001<sup>b</sup> |
|                      | Median (IQR) | 17.9 (16.9; 18.6) | 18.5 (17.7; 18.9) | 18.3 (17.7; 18.8) | 17.6 (16.6; 18.3) |                     |
| Perfusion density    | Mean (SD) | 0.43 (0.04)     | 0.44 (0.03)    | 0.44 (0.03)      | 0.43 (0.04)      | < 0.001<sup>b</sup> |
|                      | Median (IQR) | 0.45 (0.42; 0.46) | 0.45 (0.44; 0.46) | 0.45 (0.43; 0.46) | 0.44 (0.41; 0.46) |                     |
| Area (mm2)           | Mean (SD) | 0.24 (0.1)      | 0.24 (0.09)    | 0.23 (0.09)      | 0.24 (0.11)      | 0.541               |
|                      | Median (IQR) | 0.23 (0.16; 0.3) | 0.24 (0.18; 0.29) | 0.22 (0.17; 0.29) | 0.23 (0.16; 0.3) |                     |
| Perimeter (mm)       | Mean (SD) | 1.96 (0.48)     | 1.96 (0.4)     | 1.94 (0.43)      | 1.97 (0.51)      | 0.537               |
|                      | Median (IQR) | 1.97 (1.66; 2.3) | 2 (1.71; 2.2)  | 1.89 (1.67; 2.2) | 1.98 (1.64; 2.3) |                     |
| Circularity          | Mean (SD) | 0.73 (0.08)     | 0.76 (0.07)    | 0.74 (0.08)      | 0.73 (0.08)      | 0.016               |
|                      | Median (IQR) | 0.75 (0.69; 0.79) | 0.77 (0.73; 0.82) | 0.75 (0.69; 0.8) | 0.74 (0.69; 0.79) |                     |

SD, indicates standard deviation; IQR, interquartile range.
<sup>a</sup>Generalized Estimating Equation (GEE). Unadjusted P value.
<sup>b</sup>Generalized Estimating Equation (GEE). Adjusted P value < 0.05 (adjusted for age, gender, signal strength index (SSI), axial length, and diabetic retinopathy stage).

---
Figure 5. Receiver operating curves (ROC) of Optical Coherence Tomography Angiography (OCTA) parameters in 3 × 3 mm scans. Subgroup analysis by controls (left column), patients with type 1 diabetes mellitus with no diabetic retinopathy (middle column) and with diabetic retinopathy (mild, moderate, and severe nonproliferative and proliferative diabetic retinopathy)(right column). Top row: vessel density; Top-middle row: perfusion density; Middle row: Foveal Avascular Zone (FAZ) area; Middle-bottom row: FAZ perimeter; Bottom row: FAZ circularity. AUC, area under the curve; CI, confidence interval.
Table 3. Selection of Relevant Papers Published to Date on OCTA and Diabetes Mellitus (n ≥ 25), Ordered by Diabetes Mellitus Type, Sample Size, and Publication Year

| Author               | Year | Type of Diabetes | Total | Type 1 | Type 2 | OCTA Parameter | Vascular Plexus | OCTA Device | Software |
|----------------------|------|------------------|-------|--------|--------|----------------|----------------|-------------|----------|
| Carnevali et al.     | 2017 | Both             | 62    | ?      | 29     | 33             | VD, FAZ        | S, D, CC    | Built in |
| Sacconi et al.       | 2019 | Both             | 96    | ?      | 61     | 35             | VD, FAZ        | S, D, CC    | Built in |
| Li et al.            | 2019 | Both             | 122   | ?      | 94     | 38             | VD, FAZ        | S, D, CC    | Built in |
| Mameli et al.        | 2019 | Both             | 160   | ?      | 117    | 43             | VD, FAZ        | S, D, CC    | Built in |
| Inanc et al.         | 2019 | Both             | 162   | ?      | 142    | 20             | FAZ            | S, D        | Built in |
| Niestrata-Ortiz et al.| 2019 | Both             | 164   | ?      | 248    | 188            | VD, FAZ        | S, D        | Built in |
| Dimitrova et al.     | 2019 | Both             | 168   | ?      | 76     | 90             | VD, FAZ        | S, D        | Built in |
| Lupidi et al.        | 2019 | Both             | 174   | ?      | 91     | 83             | VD, FAZ        | S, D        | Built in |
| Golan et al.         | 2019 | Both             | 176   | ?      | 101    | 83             | VD, FAZ        | S, D, CC    | Built in |
| De Carlo et al.      | 2019 | Both             | 180   | ?      | 153    | 104            | VD, FAZ        | S, D, CC    | Built in |
| Vujosevic et al.     | 2019 | Both             | 184   | ?      | 181    | 137            | VD, FAZ        | S, D, CC    | Built in |
| Rodrigues et al.     | 2019 | Both             | 188   | ?      | 434    | 434            | VD, FAZ        | S, D        | Built in |
| Choi et al.          | 2019 | Both             | 192   | ?      | 447    | 447            | VD, FAZ        | S, D        | Built in |
| Rosen et al.         | 2019 | Both             | 196   | ?      | 152    | 89             | VD, FAZ        | S, M, D, CC | Built in |
| Nesper et al.        | 2019 | Both             | 200   | ?      | 111    | 55             | VD, FAZ        | S, D        | Built in |
| Tang et al.          | 2019 | Both             | 204   | ?      | 434    | 434            | VD, FAZ        | S, D        | Built in |
| Koh et al.           | 2019 | Both             | 208   | ?      | 447    | 447            | VD, FAZ        | S, D        | Built in |
| Ishibazawa et al.    | 2015 | Undisclosed      | 47    | ?      | 47     | 47             | VD, FAZ        | S, D        | Built in |
| Shen et al.          | 2018 | Undisclosed      | 90    | ?      | 49     | 49             | VD, FAZ        | S, D        | Built in |
| Samara et al.        | 2017 | Undisclosed      | 118   | ?      | 84     | 84             | VD, FAZ        | S, D        | Built in |
| Mastropasqua et al.  | 2019 | Undisclosed      | 119   | ?      | 94     | 94             | VD, FAZ        | S, D, CC    | Built in |
| Conti et al.         | 2018 | Undisclosed      | 136   | ?      | 99     | 99             | VD, FAZ        | S, D, CC    | Built in |
| Onishi et al.        | 2018 | Undisclosed      | 180   | ?      | 136    | 136            | VD, FAZ        | S, M, D     | Built in |
| Yang et al.          | 2019 | Undisclosed      | 282   | ?      | 239    | 239            | VD, FAZ        | S, D        | Built in |
| Cao et al.           | 2018 | Undisclosed      | 138   | ?      | 71     | 67             | VD, FAZ        | S, D, CC    | Built in |
| Ting et al.          | 2017 | 1                | 100   | 100    | 100    | 100            | VD, FAZ        | S, D        | Built in |
| Tan et al.           | 2019 | 1                | 212   | 212    | 212    | 212            | VD, FAZ        | S, D        | Built in |
| Zeng et al.          | 2019 | 1                | 170   | 170    | 170    | 170            | VD, FAZ        | S, D        | Built in |
| Kim et al.           | 2018 | 1                | 155   | 155    | 155    | 155            | VD, FAZ        | S, D        | Built in |
| This study           | 2020 | 1                | 1186  | 956    | 230    | 230            | VD, FAZ        | S          | Built in |

OCTA, optical coherence tomography angiography; DM, diabetes mellitus; VD, vessel density; PD, perfusion density; FAZ, foveal avascular zone; S, superficial; M, medium; D, deep; CC, choriocapillaris; RS, research software.

Note: The OCTA parameters may not have been described in the original papers exactly as those described in the table, as the terms have been unified for comparison purposes. Devices: Cirrus Angioplex, Carl Zeiss Meditec, Dublin, CA; PLEX Elite 9000, Carl Zeiss Meditec, Inc., Dublin, CA; RTVue XR Avanti, Optovue Inc., Fremont, CA; Angiovue System, Optovue Inc., Fremont, CA; DRI OCT-A Triton Plus, Topcon Europe, Milano; Spectralis OCT2, Heidelberg Engineering, Heidelberg. (*) = see “References” section.
25 eyes that OCTA was able to detect early vascular alterations even without any biomicroscopic signs of DR. More recently, Sacconi et al. described a series of 34 eyes where the only OCTA parameter that was significantly different in patients with type 1 DM compared to controls was the PD of the DCP, without differences in the rest of the studied parameters and plexuses. The largest series in type 1 DM have been described in children, and they interestingly have shown controversial results. Golebiowska et al. reported that no differences were seen in the VD or FAZ area in any of the studied plexuses between patients with type 1 DM and controls (n = 188 vs. 60); however, Niestrata-Ortiz et al. described that FAZ area was different between diabetic and healthy children (n = 112 vs. 30). In this last paper, a greater FAZ area was also associated with a longer duration of the disease. Obviously, the mean age of the study cohorts in these pediatric series (15.3 and 13.8 years, respectively) needs to be considered when interpreting these results, in order to allow meaningful comparisons with adult populations.

One of the key issues when interpreting quantitative analysis of OCTA images is which retinal plexus is being evaluated, a feature that is strongly related to the OCT device used for the image capture and the segmentation algorithm used by the software of the machine. In this report, we have used an OCT device that allows measurements only in the SCP with the commercial built-in software. The role of the different plexuses in the pathophysiology of DR is also a controversial topic, and there are discrepancies in the literature. Again, for the reasons mentioned above, most of the current evidence about which plexus and OCTA parameter reflects better the status of the macula of patients with diabetes needs to be taken from type 2 DM studies. Agemy et al. reported that VD measurements were different in the SCP and DCP of diabetic eyes, meanwhile Coscas et al. did not find any significant differences between these two plexuses in patients with diabetes. These controversial findings may be explained at least in part for the small sample size of these studies, and it is still unclear whether both plexuses are or are not affected simultaneously, limiting the conclusions of these previous reports. Consistently with our findings, several previous studies have found a lower VD in patients with DR compared with healthy controls, as well as an association between lower VD and greater DR stages in both SCP and DCP. What is clinically meaningful is that OCTA has demonstrated the ability to distinguish between healthy eyes and eyes with different stages of DR severity, using automated algorithms to measure different flow parameters in the macula. In order to provide helpful data for this differentiation, cut off points for each individual OCTA parameter are suggested in this paper, based on the ROC curves presented for controls and patients with type 1 DM without and with DR.

FAZ alterations are commonly seen in patients with diabetes. Previous studies in type 2 DM have shown that diabetic eyes are more likely to have an enlarged FAZ compared to healthy control eyes. Consistently with that, in our study, we found that in patients with type 1 DM the FAZ perimeter and area were progressively larger in greater DR stages but decreased in proliferative diabetic retinopathy (PDR) cases, both in 3 × 3 and 6 × 6 mm captures. We hypothesize that this finding in PDR cases may be explained by the reduced retinal thickness of these eyes and the fact that most of our PDR cases were previously treated with laser PRP in the moment of the scan, raising the interesting hypothesis of central reperfusion after PRP laser treatment. However, this is a controversial topic, as a significant variability in the FAZ area has been described in healthy individuals, and, therefore, it is difficult to determine a threshold between FAZ normality and pathological enlargement in retinal diseases. For this reason, the FAZ area may not be a sensitive marker to establish whether a study eye is normal or presents a retinal disease, but in some retinal conditions, as in DR, it may be associated with greater DR stages. As previously described, in this paper, we suggest potential cut offs for each of the FAZ parameters in ROC curves for controls and diabetic eyes without and with DR, in order to provide clinically relevant data to the ophthalmic community. Interestingly, Kim et al. showed a significant correlation between FAZ irregularity and visual acuity (VA). This parameter, FAZ circularity, may be helpful to objectively quantify the perifoveal capillary ring disruption and may potentially be a better tool to establish the degree of microvascular damage in the FAZ, which is ultimately related to VA.

The main strength of this study is the large number of type 1 DM eyes included, which to date is the largest OCTA cohort published in these patients. Second, the fact of obtaining the data with the device built-in commercial software and no manual corrections present two additional benefits: to obtain reliable and objective data of the analyzed parameters and to be reproducible and generalizable to other groups, without the need to use a research software, unpractical in daily practice, and unavailable to all medical teams. Third, the inclusion of a relatively large number of controls also add significant value to the OCTA analysis performed and constitutes another strong point of this study. As previously mentioned, a potential limi-
tion of the study is the inability of the commercial software of the device used to quantify vascular flow parameters of the DCP, which, according to some authors, may be affected earlier in the development of DR. Future analysis of our dataset using an automated research software will shed some light on this specific issue. Nevertheless, our results have already detected flow alterations in the SCP indicating that this plexus has a determining role in the DR pathophysiology from early stages of the disease. Another possible limitation of the study may be the small number of patients with DM with severe NPDR, due to the efficacy of the public DR screening program in Spain. As the majority of the study cohort presented the milder forms of the disease, the results of this study are especially representative of early DR stages with a relatively spared macular anatomy. This may have had a positive effect in the reliability of the OCTA-derived metrics obtained, with a low rate of artifacts compared to other reported series in pathological eyes. However, the early stages of DR are the ones that may present subclinical signs that are worth detecting as soon as possible, in order to allow early interventions and to stop the progression of the disease.

In conclusion, OCTA is able to detect microvascular changes in type 1 DM diabetic eyes, which are correlated with the DR stage independently of age and duration of DM disease. Quantitative parameters as VD, PD, and FAZ area, circularity, or perimeter may be objectively quantified in diabetic eyes with this noninvasive technology. This automated analysis reveals details of the perifoveal vascular network status in an objective way, translating subjective qualitative findings into objective data, a significant step forward to allow ophthalmologists the integration of meaningful retinal vascularity data in daily clinical practice. These findings suggest a major role of OCTA in the next future, as these microvascular changes may be detected in their preclinical status, before the first clinical signs of DR appear in direct fundus examination. Future studies will focus on the possibility of defining OCTA-derived parameter ranges for DR severity stage classification, risk assessment, and, maybe, response to treatment and monitorization based on these objective grounds.

Acknowledgments

The authors thank Fundació La Marató de TV3 for the funding received and Fundació Clinic (especially to Francesca Vidal) for the administrative support given for this study.

Trial Sponsor: Fundació Clinic per a la Recerca Biomèdica, Hospital Clínic de Barcelona. C/ Roselló, 149-153, 08036, Barcelona.

Financial Support: Fundació La Marató de TV3, La Marató 2015, Diabetis i Obesitat (grant number 201633.10) and Instituto de Salud Carlos III, (through the project PI18/00518, co-funded by European Regional Development Fund “Investing in your future”). This study has undergone peer-review separately by both funding bodies. None of the funding bodies have had any access to the study design, the study data or the study conclusions.

Ethics approval and consent to participate: This study was approved by the Institutional Review Board of Hospital Clínic de Barcelona. All participants provided written informed consent prior to inclusion in the study.

Consent for publication: All participants provided written informed consent prior to inclusion in the study.

Availability of data and material: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author’s contributions: Conception and study design (J.Z.V., I.V., E.O., E.E., and A.A.), literature search (M.B., J.Z.V., A.S.P., and M.F.R.), data collection (M.B., A.A.C., T.H., C.O., J.G., and J.Z.V.), statistical expertise (J.Z.V. and C.E.), analysis and interpretation (M.B., J.Z.V., A.A.C., A.S.P., M.F.R., I.V., E.O., E.E., and A.A.), writing the article (M.B. and J.Z.V.), critical revision of the manuscript (M.B., J.Z.V., A.A.C., A.S.P., M.F.R., I.V., C.E., E.O., and A.A.), final approval of the manuscript (M.B., J.Z.V., A.A.C., T.H., C.O., J.G., A.S.P., M.F.R., I.V., E.O., C.E., E.E., and A.A.). All authors have read and approved the manuscript.

Disclosure: M. Barraso, None; A. Alé-Chilet, None; T. Hernández, None; C. Oliva, None; I. Vinagre, None; E. Ortega, None; M. Figueras-Roca, None; A. Sala-Puigdollers, None; C. Esquinas, None; E. Esmatjes, None; A. Adán, None; J. Zarranz-Ventura, None

References

1. Zhang K, Ferreyra HA, Grob S, Bedell M, Zhang JJ. Diabetic Retinopathy. In: Retina. Elsevier; 2013:925–939.
2. Shah C. Diabetic retinopathy: a comprehensive review. Indian J Med Sci. 2008;62:500.
3. Jia Y, Bailey ST, Hwang TS, et al. Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. Proc Natl Acad Sci. 2015;112:E2395–E2402.
4. Ishibazawa A, Nagaoka T, Takahashi A, et al. Optical coherence tomography angiography in diabetic retinopathy: a prospective pilot study. Am J Ophthalmol. 2015;160:35–44.e1.
5. Wu L. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4:290.
6. Ting DSW, Tan GSW, Agrawal R, et al. Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. Acta Diabetol. 2018;55:469–477.
7. Shen C, Yan S, Du M, Zhao H, Shao L, Hu Y. Optical coherence tomography angiography of retinal and choroidal vasculature – function correlation in non-proliferative diabetic retinopathy. Doc Ophthalmol. 2019;140:129–138.
8. Zeng Y, Cao D, Yang D, et al. Retinal vascular – function correlation in non-proliferative diabetic retinopathy. Acta Diabetol. 2019;56:1293–1303.
9. Sacconi R, Casaluci M, Borrelli E, et al. Multimodal imaging assessment of vascular and neurodegenerative retinal alterations in type 1 diabetic patients without fundoscopic signs of diabetic retinopathy. J Clin Med. 2019;8:1409.
26. Li T, Jia Y, Wang S, et al. Retinal microvascular abnormalities in children with type 1 diabetes mellitus without visual impairment or diabetic retinopathy. *Investig Ophthalmol Vis Sci.* 2019;60:990–998.

27. Gołębiewska J, Olechowski A, Wysocka-Minciewicz M, et al. Optical coherence tomography angiography vessel density in children with type 1 diabetes. Malik RA, ed. *PLoS One.* 2017;12:e0186479.

28. Niestrata-Ortiz M, Fichna P, Stankiewicz W, Stopa M. Enlargement of the foveal avascular zone detected by optical coherence tomography angiography in diabetic children without diabetic retinopathy. *Graefe’s Arch Clin Exp Ophthalmol.* 2019;257:689–697.

29. Mameli C, Invernizzi A, Bolchini A, et al. Analysis of retinal perfusion in children, adolescents, and young adults with type 1 diabetes using optical coherence tomography angiography. *J Diabetes Res.* 2019;2019:1–8.

30. Inanc M, Tekin K, Kiziltoprak H, Ozalkak S, Doguizi S, Aycan Z. Changes in retinal microcirculation precede the clinical onset of diabetic retinopathy in children with type 1 diabetes mellitus. *Am J Ophthalmol.* 2019;207:37–44.

31. Agemy SA, Scripsema NK, Shah CM, et al. Retinal vascular perfusion density mapping using optical coherence tomography angiography in normals and diabetic retinopathy patients. *Retina.* 2015;35:2353–2363.

32. Coscas G, Lupidi M, Coscas F, Chhablani J, Cagini C. Optical coherence tomography angiography in healthy subjects and diabetic patients. *Ophthalmologica.* 2018;239:61–73.

33. Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH. Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography. *Investig Ophthalmol Vis Sci.* 2016;57:OCT362–OCT370.

34. Dimitrova G, Chihara E, Takahashi H, Amano H, Okazaki K. Quantitative retinal optical coherence tomography angiography in patients with diabetes without diabetic retinopathy. *Investig Ophthalmol Vis Sci.* 2017;58:190–196.

35. De Carlo TE, Chin AT, Bonini Filho MA, et al. Detection of microvascular changes in eyes of patients with diabetes but not clinical diabetic retinopathy using optical coherence tomography angiography. *Retina.* 2015;35:2364–2370.

36. Hwang TS, Gao SS, Liu L, et al. Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy. *JAMA Ophthalmol.* 2016;134:367–373.

37. Nesper PL, Roberts PK, Onishi AC, et al. Quantifying microvascular abnormalities with increasing severity of diabetic retinopathy using optical coherence tomography angiography. *Invest Ophthalmol Vis Sci.* 2017;58:BIO307–BIO315.

38. Nesper PL, Soetikno BT, Zhang HF, Fawzi AA. OCT angiography and visible-light OCT in diabetic retinopathy. *Vision Res.* 2017;139:191–203.

39. Carpineto P, Mastropasqua R, Marchini G, Toto L, Di Nicola M, Di Antonio L. Reproducibility and repeatability of foveal avascular zone measurements in healthy subjects by optical coherence tomography angiography. *Br J Ophthalmol.* 2016;100:671–676.

40. Holmen IC, Konda SM, Pak JW, et al. Prevalence and severity of artifacts in optical coherence tomographic angiograms. *JAMA Ophthalmol.* 2020;138:119.

41. Tang F, Sun Z, Wong R, et al. Relationship of intercapillary area with visual acuity in diabetes mellitus: an optical coherence tomography angiography study. *Br J Ophthalmol.* 2019;103:604–609.

42. Samara WA, Shahlkea A, Adam MK, et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. *Ophthalmology.* 2017;124:235–244.

43. Tan F, Chen Q, Zhuang X, et al. Associated risk factors in the early stage of diabetic retinopathy. *Eye Vis.* 2019;6:23.